Back to Journals » International Journal of Nanomedicine » Volume 11

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Authors Berce C, Lucan C, Petrushev B, Boca S, Miclean M, Sarpataki O, Astilean S, Buzoianu A, Tomuleasa C, Bojan A

Received 17 March 2016

Accepted for publication 1 June 2016

Published 1 September 2016 Volume 2016:11 Pages 4261—4273


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Thomas J Webster

Cristian Berce,1,* Ciprian Lucan,2,* Bobe Petrushev,3,4 Sanda Boca,5 Mirela Miclean,6 Orsolya Sarpataki,7 Simion Astilean,5 Anca Buzoianu,8 Ciprian Tomuleasa,3,9 Anca Bojan9,10

1Animal Facility, 2Department of Surgery, 3Research Center for Functional Genomics and Translational Medicine, 4Department of Pathology, Iuliu Hatieganu University of Medicine and Pharmacy, 5Nanobiophotonics and Laser Microscopy Center, Interdisciplinary Research in Bio-Nano-Sciences – Faculty of Physics, Babes-Bolyai University, 6Institute for Research in Analytical Instruments, 7Department of Pathophysiology, University of Veterinary Medicine, 8Department of Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, 9Department of Hematology, Ion Chiricuta Oncology Institute, 10Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

*These authors contributed equally to this work

Introduction: The present study aimed at evaluating the biodistribution of Tween® 20-gold nanoparticle (GNP) conjugates and their potential toxicity on the bone marrow before moving on to Phase I clinical trials.
Materials and methods: Tween® 20-conjugated GNPs were injected intravenously for 21 days in male Crl:CD1(ICR) mice. Body weight of the mice was evaluated each day. After the sub-chronic Tween® 20-GNPs administration, blood samples were harvested, and a full blood count was done individually. Total Au quantity from all major organs was assessed using inductively coupled plasma mass spectrometry. One femur and the sternum obtained from each animal were used for histological assessment.
Results: Our data showed that the Tween® 20-GNP conjugates were found in large quantities in the bladder. Au was shown to accumulate in the hematopoietic bone tissue, with significant side effects such as leucopoiesis and megakaryopoiesis. The mice had a higher white blood cell and platelet count as opposed to the control group. This suggested that the previously described leukopenic effects of isoflurane were overridden by the leucopoietic effects of Tween® 20-GNPs.
Conclusion: It was uncertain whether the mice were reactive to Au as it is a foreign substance to the tissues or whether the side effects observed were a precursor condition of a more severe hematological condition. Au was found to be hepatotoxic, urging the need for further studies in order to achieve better in vivo compliance and exploit the immense potential of GNPs in cancer pharmacology.

Keywords: GNPs, Tween® 20, in vivo toxicology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR–ABL transcripts

Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C

OncoTargets and Therapy 2017, 10:5047-5051

Published Date: 19 October 2017

The use of rotation to fentanyl in cancer-related pain

Dima D, Tomuleasa C, Frinc I, Pasca S, Magdo L, Berindan-Neagoe I, Muresan M, Lisencu C, Irimie A, Zdrenghea M

Journal of Pain Research 2017, 10:341-348

Published Date: 9 February 2017

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy

Petrushev B, Boca S, Simon T, Berce C, Frinc I, Dima D, Selicean S, Gafencu GA, Tanase A, Zdrenghea M, Florea A, Suarasan S, Dima L, Stanciu R, Jurj A, Buzoianu A, Cucuianu A, Astilean S, Irimie A, Tomuleasa C, Berindan-Neagoe I

International Journal of Nanomedicine 2016, 11:641-660

Published Date: 15 February 2016

Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation

Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, Dima D, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C

International Journal of Nanomedicine 2015, 10:4897-4899

Published Date: 31 July 2015

Bicytopenia as a paraneoplastic syndrome for pseudomyxoma peritonei. Hematologic manifestations of a subtle disease

Tomuleasa C, Petrushev B, Vedean M, Irimie A, Zaharie F, Rosu AM, Dima D, Cucuianu A

International Journal of General Medicine 2015, 8:93-95

Published Date: 2 March 2015

Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies

Kojima S, Cucuianu A, Takahashi Y, Berindan-Neagoe I, Florian IS, Dima D, Tomuleasa C

International Journal of Nanomedicine 2014, 9:3247-3248

Published Date: 4 July 2014

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?

Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I

International Journal of Nanomedicine 2013, 8:4043-4044

Published Date: 23 October 2013